Opus Genetics, Inc.·4

Sep 11, 6:03 PM ET

Gagnon Robert E. 4

4 · Opus Genetics, Inc. · Filed Sep 11, 2025

Insider Transaction Report

Form 4
Period: 2025-09-02
Gagnon Robert E.
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2025-09-10+200,000200,000 total
  • Award

    Employee Stock Option (right to buy)

    2025-09-02+250,000250,000 total
    Exercise: $1.23Exp: 2035-09-01Common Stock (250,000 underlying)
Footnotes (2)
  • [F1]Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.
  • [F2]The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.

Documents

1 file
  • 4
    form4.xmlPrimary